Cyclandelate in diabetic neuropathy. A double-blind, placebo-controlled, randomized, cross-over study.
Cyclandelate has the ability to improve the rheological properties of the blood and therefore may improve blood supply of peripheral nerves. Previous studies in diabetic neuropathy have shown beneficial effects of the drug. We performed a double-blind, placebo-controlled, cross-over study in 40 diabetic patients with cyclandelate in a dose of 1600 mg daily. Motor and sensory nerve conduction velocities, late responses, thermal discrimination thresholds, vibration perception thresholds and pain scores were studied. We were not able to show any positive effect of the drug and therefore conclude that cyclandelate is not effective in the treatment of diabetic neuropathy.
Heimans
J J
JJ
Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.
Drukarch
B
B
Matthaei
I
I
Ijff
G A
GA
Bertelsmann
F W
FW
Strijers
R L
RL
Nauta
J
J
D000328:Adult; D000368:Aged; D003495:Cyclandelate / Q000627:therapeutic use*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010543:Peroneal Nerve / Q000187:drug effects; D012684:Sensory Thresholds / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects
D003495:Cyclandelate